,address1,city,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,16 Tiomkin Street,Tel Aviv,6578317,Israel,972 3 693 8448,972 3 693 8447,https://www.galmedpharma.com,Biotechnology,Healthcare,"Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.",4,"{'maxAge': 1, 'name': 'Mr. Allen  Baharaff', 'age': 57, 'title': 'Co-Founder, Pres, CEO & Chairman', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 803501, 'exercisedValue': 0, 'unexercisedValue': 146192}",1672444800,86400,4,0.7509,0.750901,0.7399,0.76,0.7509,0.750901,0.7399,0.76,0.0,0.944329,-0.5440441,8682,8682,285243,22620,22620,0.71,0.75,1000,1100,2816939,0.29,5.63,1.09898,1.27101,0.0,0.0,USD,-8068314,0.0,1335180,3807190,7162,27534,1690761600,1693440000,0.0019,0.112840004,0.15257,0.13,0.002,6.281,0.11779971,1672444800,1703980800,1688083200,-11412000,-6.42,-1.36,-0.02,0.691,NCM,EQUITY,GLMD,GLMD,Galmed Pharmaceuticals Ltd.,Galmed Pharmaceuticals Ltd.,1394717400,America/New_York,EDT,-14400000,0.7399,4.0,4.0,4.0,4.0,2.0,buy,1,9330000,5.553,-11668000,0,3.552,3.594,-0.39693,-0.72999,-6150750,-10200000,0.0,0.0,0.0,USD,
1,16 Tiomkin Street,Tel Aviv,6578317,Israel,972 3 693 8448,972 3 693 8447,https://www.galmedpharma.com,Biotechnology,Healthcare,"Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.",4,"{'maxAge': 1, 'name': 'Mr. Doron  Cohen', 'age': 55, 'title': 'Chief Financial Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 175332, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.7509,0.750901,0.7399,0.76,0.7509,0.750901,0.7399,0.76,0.0,0.944329,-0.5440441,8682,8682,285243,22620,22620,0.71,0.75,1000,1100,2816939,0.29,5.63,1.09898,1.27101,0.0,0.0,USD,-8068314,0.0,1335180,3807190,7162,27534,1690761600,1693440000,0.0019,0.112840004,0.15257,0.13,0.002,6.281,0.11779971,1672444800,1703980800,1688083200,-11412000,-6.42,-1.36,-0.02,0.691,NCM,EQUITY,GLMD,GLMD,Galmed Pharmaceuticals Ltd.,Galmed Pharmaceuticals Ltd.,1394717400,America/New_York,EDT,-14400000,0.7399,4.0,4.0,4.0,4.0,2.0,buy,1,9330000,5.553,-11668000,0,3.552,3.594,-0.39693,-0.72999,-6150750,-10200000,0.0,0.0,0.0,USD,
2,16 Tiomkin Street,Tel Aviv,6578317,Israel,972 3 693 8448,972 3 693 8447,https://www.galmedpharma.com,Biotechnology,Healthcare,"Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.",4,"{'maxAge': 1, 'name': 'Mr. Guy  Nehemya', 'age': 37, 'title': 'COO & Data Protection Officer', 'yearBorn': 1985, 'fiscalYear': 2022, 'totalPay': 235560, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.7509,0.750901,0.7399,0.76,0.7509,0.750901,0.7399,0.76,0.0,0.944329,-0.5440441,8682,8682,285243,22620,22620,0.71,0.75,1000,1100,2816939,0.29,5.63,1.09898,1.27101,0.0,0.0,USD,-8068314,0.0,1335180,3807190,7162,27534,1690761600,1693440000,0.0019,0.112840004,0.15257,0.13,0.002,6.281,0.11779971,1672444800,1703980800,1688083200,-11412000,-6.42,-1.36,-0.02,0.691,NCM,EQUITY,GLMD,GLMD,Galmed Pharmaceuticals Ltd.,Galmed Pharmaceuticals Ltd.,1394717400,America/New_York,EDT,-14400000,0.7399,4.0,4.0,4.0,4.0,2.0,buy,1,9330000,5.553,-11668000,0,3.552,3.594,-0.39693,-0.72999,-6150750,-10200000,0.0,0.0,0.0,USD,
3,16 Tiomkin Street,Tel Aviv,6578317,Israel,972 3 693 8448,972 3 693 8447,https://www.galmedpharma.com,Biotechnology,Healthcare,"Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.",4,"{'maxAge': 1, 'name': 'Mr. Yohai  Stenzler CPA', 'age': 39, 'title': 'Chief Accounting Officer', 'yearBorn': 1983, 'fiscalYear': 2022, 'totalPay': 239482, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.7509,0.750901,0.7399,0.76,0.7509,0.750901,0.7399,0.76,0.0,0.944329,-0.5440441,8682,8682,285243,22620,22620,0.71,0.75,1000,1100,2816939,0.29,5.63,1.09898,1.27101,0.0,0.0,USD,-8068314,0.0,1335180,3807190,7162,27534,1690761600,1693440000,0.0019,0.112840004,0.15257,0.13,0.002,6.281,0.11779971,1672444800,1703980800,1688083200,-11412000,-6.42,-1.36,-0.02,0.691,NCM,EQUITY,GLMD,GLMD,Galmed Pharmaceuticals Ltd.,Galmed Pharmaceuticals Ltd.,1394717400,America/New_York,EDT,-14400000,0.7399,4.0,4.0,4.0,4.0,2.0,buy,1,9330000,5.553,-11668000,0,3.552,3.594,-0.39693,-0.72999,-6150750,-10200000,0.0,0.0,0.0,USD,
4,16 Tiomkin Street,Tel Aviv,6578317,Israel,972 3 693 8448,972 3 693 8447,https://www.galmedpharma.com,Biotechnology,Healthcare,"Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.",4,"{'maxAge': 1, 'name': 'Dr. Liat  Hayardeny', 'age': 55, 'title': 'Chief Scientific Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 125243, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.7509,0.750901,0.7399,0.76,0.7509,0.750901,0.7399,0.76,0.0,0.944329,-0.5440441,8682,8682,285243,22620,22620,0.71,0.75,1000,1100,2816939,0.29,5.63,1.09898,1.27101,0.0,0.0,USD,-8068314,0.0,1335180,3807190,7162,27534,1690761600,1693440000,0.0019,0.112840004,0.15257,0.13,0.002,6.281,0.11779971,1672444800,1703980800,1688083200,-11412000,-6.42,-1.36,-0.02,0.691,NCM,EQUITY,GLMD,GLMD,Galmed Pharmaceuticals Ltd.,Galmed Pharmaceuticals Ltd.,1394717400,America/New_York,EDT,-14400000,0.7399,4.0,4.0,4.0,4.0,2.0,buy,1,9330000,5.553,-11668000,0,3.552,3.594,-0.39693,-0.72999,-6150750,-10200000,0.0,0.0,0.0,USD,
5,16 Tiomkin Street,Tel Aviv,6578317,Israel,972 3 693 8448,972 3 693 8447,https://www.galmedpharma.com,Biotechnology,Healthcare,"Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.",4,"{'maxAge': 1, 'name': 'Ms. Yael  Hollander', 'age': 39, 'title': 'VP of Legal Affairs & Strategy', 'yearBorn': 1983, 'fiscalYear': 2017, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.7509,0.750901,0.7399,0.76,0.7509,0.750901,0.7399,0.76,0.0,0.944329,-0.5440441,8682,8682,285243,22620,22620,0.71,0.75,1000,1100,2816939,0.29,5.63,1.09898,1.27101,0.0,0.0,USD,-8068314,0.0,1335180,3807190,7162,27534,1690761600,1693440000,0.0019,0.112840004,0.15257,0.13,0.002,6.281,0.11779971,1672444800,1703980800,1688083200,-11412000,-6.42,-1.36,-0.02,0.691,NCM,EQUITY,GLMD,GLMD,Galmed Pharmaceuticals Ltd.,Galmed Pharmaceuticals Ltd.,1394717400,America/New_York,EDT,-14400000,0.7399,4.0,4.0,4.0,4.0,2.0,buy,1,9330000,5.553,-11668000,0,3.552,3.594,-0.39693,-0.72999,-6150750,-10200000,0.0,0.0,0.0,USD,
6,16 Tiomkin Street,Tel Aviv,6578317,Israel,972 3 693 8448,972 3 693 8447,https://www.galmedpharma.com,Biotechnology,Healthcare,"Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.",4,"{'maxAge': 1, 'name': 'Ms. Shani  Ganon', 'title': 'HR Mang.', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.7509,0.750901,0.7399,0.76,0.7509,0.750901,0.7399,0.76,0.0,0.944329,-0.5440441,8682,8682,285243,22620,22620,0.71,0.75,1000,1100,2816939,0.29,5.63,1.09898,1.27101,0.0,0.0,USD,-8068314,0.0,1335180,3807190,7162,27534,1690761600,1693440000,0.0019,0.112840004,0.15257,0.13,0.002,6.281,0.11779971,1672444800,1703980800,1688083200,-11412000,-6.42,-1.36,-0.02,0.691,NCM,EQUITY,GLMD,GLMD,Galmed Pharmaceuticals Ltd.,Galmed Pharmaceuticals Ltd.,1394717400,America/New_York,EDT,-14400000,0.7399,4.0,4.0,4.0,4.0,2.0,buy,1,9330000,5.553,-11668000,0,3.552,3.594,-0.39693,-0.72999,-6150750,-10200000,0.0,0.0,0.0,USD,
7,16 Tiomkin Street,Tel Aviv,6578317,Israel,972 3 693 8448,972 3 693 8447,https://www.galmedpharma.com,Biotechnology,Healthcare,"Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.",4,"{'maxAge': 1, 'name': 'Dr. Tali  Gorfine', 'age': 52, 'title': 'Medical Consultant', 'yearBorn': 1970, 'fiscalYear': 2020, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.7509,0.750901,0.7399,0.76,0.7509,0.750901,0.7399,0.76,0.0,0.944329,-0.5440441,8682,8682,285243,22620,22620,0.71,0.75,1000,1100,2816939,0.29,5.63,1.09898,1.27101,0.0,0.0,USD,-8068314,0.0,1335180,3807190,7162,27534,1690761600,1693440000,0.0019,0.112840004,0.15257,0.13,0.002,6.281,0.11779971,1672444800,1703980800,1688083200,-11412000,-6.42,-1.36,-0.02,0.691,NCM,EQUITY,GLMD,GLMD,Galmed Pharmaceuticals Ltd.,Galmed Pharmaceuticals Ltd.,1394717400,America/New_York,EDT,-14400000,0.7399,4.0,4.0,4.0,4.0,2.0,buy,1,9330000,5.553,-11668000,0,3.552,3.594,-0.39693,-0.72999,-6150750,-10200000,0.0,0.0,0.0,USD,
